|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | National Center for Research Resources (NCRR) |
|---|---|
| Collaborator: |
Oregon Health and Science University |
| Information provided by: | National Center for Research Resources (NCRR) |
| ClinicalTrials.gov Identifier: | NCT00004345 |
Purpose
OBJECTIVES: I. Examine the concentration of docosahexanoic acid (DHA) and other n-3 fatty acids in plasma, erythrocyte, and adipose tissue in patients with various forms of retinitis pigmentosa and Usher syndrome.
II. Determine the synthesis and catabolism of DHA from linolenic acid in these patients.
III. Determine the synthesis, absorption, and catabolism of DHA under different dietary conditions in these patients.
| Condition |
|---|
|
Usher Syndrome Retinitis Pigmentosa |
| Study Type: | Observational |
| Study Design: | Screening |
| Estimated Enrollment: | 100 |
| Study Start Date: | October 1999 |
PROTOCOL OUTLINE: Patients may participate in one or more of the arms of this study.
Arm I (adipose tissue study): Adipose tissue is collected from the buttocks of patients with Usher II retinitis pigmentosa (RP), patients with non-Usher RP, and control subjects. Dietary histories are obtained from all patients and subjects.
Arm II (isotope study): Patients meeting the same criteria as in arm I receive oral D5-labeled linolenic acid and oral D4-labeled linolenic acid that is dissolved in oil and incorporated into foods. Subjects must avoid eating fish and shellfish during the 35 days of the isotope study. Blood samples are collected at 0, 8, 24, and 48 hours, daily on days 3-7, and then on days 10, 18, and 35.
Arm III (flaxseed oil feeding): Patients with all types of RP and control subjects receive flaxseed oil, a form of linolenic acid, for 12 weeks. Subjects may also receive high oleic safflower oil or olive oil as a control fat for 12 weeks. Subjects complete a diet history at the end of each fatty acid supplementation period. All subjects must follow a diet free of seafood and fish oil supplements.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
PROTOCOL ENTRY CRITERIA:
Contacts and Locations| United States, Oregon | |
| Oregon Health Sciences University | |
| Portland, Oregon, United States, 97201-3098 | |
| Study Chair: | William Connor | Oregon Health and Science University |
More Information
| Study ID Numbers: | 199/11904, OHSU-2650 |
| Study First Received: | October 18, 1999 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00004345 History of Changes |
| Health Authority: | United States: Federal Government |
|
Usher syndrome ophthalmologic disorders rare disease retinitis pigmentosa |
|
Sensation Disorders Vision Disorders Retinitis Deaf-Blind Disorders Hearing Loss, Sensorineural Usher Syndromes Ear Diseases Signs and Symptoms Deafness Hearing Disorders Pathologic Processes Syndrome Retinitis Pigmentosa |
Abnormalities, Multiple Eye Diseases, Hereditary Hearing Loss Congenital Abnormalities Retinal Diseases Disease Otorhinolaryngologic Diseases Eye Diseases Nervous System Diseases Retinal Degeneration Blindness Genetic Diseases, Inborn Neurologic Manifestations |